Open
Newly Diagnosed Secondary AML Research Study
This is a research study to find out if giving a combination of drugs (tagraxofusp and azacitidine) will treat your leukemia and keep it inactive for a period of time.
Age & Gender
- 18 years ~ 99 years
- Male, Female, Gender Inclusive
Visit Availability
- Standard business hours (M-F, 8-5)
Location
United States (Nationwide)
What will be asked of you
At each study visit, you will meet with a team member who will ask you questions about your health, physical examination, vital signs, blood draws, and bone marrow biopsy at certain visits.
Incentives
Study medication
In-person visits:
8+
8+
Total length of participation:
24 months
24 months
Looking for Specific Volunteers
Able to participate:
- You have a new diagnosis of Acute Myeloid Leukemia
- You are 18 or older
- You have good kidney and liver function
Not eligible if:
- You have had previous chemotherapy treatment
- You have other previous cancer diagnosis
- You have significant heart or lung disease
- You are pregnant
Contact the Team
Visit Location
Contact & Visit Location
Primary Contact
- Lineberger Clinical Research
- cancerclinicaltrials@med.unc.edu
- (919) 966-4432
Primary Visit Location
Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Additional Study Information
Principal Investigator
Joshua Zeidner
LCCC - Clinical Trials
Study Type
Clinical or Medical
Interventional
Study Topics
Cancer (Leukemia)
IRB Number
22-1074
